

■ Accreditation

Mount Sinai Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. Mount Sinai designates this educational activity for a maximum of 11.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

■ Psychology Credit

The Mild Cognitive Impairment Symposium has been approved by the Florida Board of Psychology and the Miami Area Geriatric Education Center (MAGEC). This program has been approved for 11.5 contact hours. (MAGEC CE Broker Tracking #20-302392).

■ Disclosure Statement

All faculty and planning committee members are required to disclose relevant financial relationships with industry. This information will be disclosed and available in the Symposium Syllabus and at the meeting site. In addition, disclosure to the audience will be made by the Faculty prior to their presentations.

Mount Sinai Medical Center in accordance with the Standards for Commercial Support of the Accreditation Council for Continuing Medical Education (ACCME) will disclose the existence of any relevant financial relationships that CME planning committee members and faculty member/spouse or partner has (1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services and (2) with any commercial supporters of the activity. Faculty is also required to disclose to the audience, during their presentation, any investigational/unlabeled use that is discussed.

The intent of this disclosure is not to prevent a speaker with a significant financial or other relationship from making a presentation, but rather to provide the attendees with information on which they can make their own judgments.

■ Symposium Information

Please contact one of the following:

Warren Barker

Wien Center for Alzheimer's Disease
& Memory Disorders
Mount Sinai Medical Center
Phone: 305-674-2592 Fax: 305-674-2259
E-mail: mcisymposium@msmc.com

Yirah Ochoa

Wien Center for Alzheimer's Disease
& Memory Disorders
Mount Sinai Medical Center
Phone: 305-674-2018
E-mail: yochoa@msmc.com

Web: www.mcisymposium.org

9TH
ANNUAL

Symposium on
Mild Cognitive
Impairment

April 29 - 30
2011

Save the Date!

For information please visit:

www.mcisymposium.org

or

Email: mcisymposium@msmc.com

Mount Sinai
MEDICAL CENTER

Wien Center
4300 Alton Road
Miami Beach, FL 33140



MARK YOUR CALENDAR

9TH
ANNUAL

Mount Sinai
MEDICAL CENTER

MILD COGNITIVE IMPAIRMENT SYMPOSIUM

“Theme for 2011: New Criteria for Prodromal and Preclinical Alzheimer’s Disease”

Presented By:

Mount Sinai Medical Center, Miami Beach, Florida

FRIDAY – SATURDAY

April 29-30, 2011

Symposium Location:

Eden Roc Hotel

4525 Collins Avenue

Miami Beach, FL 33140

Program Director:

Ranjan Duara, MD

Medical Director, Wien Center for Alzheimer’s Disease and Memory Disorders

Mount Sinai Medical Center, Miami Beach, FL

■ Needs Assessment

Unless ways are found to prevent Alzheimer's Disease (AD) or delay its onset, it is projected that 13 million people in the United States will have AD by 2050. Individuals with AD suffer from cognitive and functional impairment, loss of productivity and significant deterioration in over-all quality of life. Most will develop problematic behaviors and many will need long-term care. In addition, caregivers of the patients are often affected by physical burden, emotional distress and financial hardship.

Since the development of criteria for AD almost twenty-five years ago, there have been major advances in our understanding of the biology and early clinical features of AD and other causes of dementia. This has led to improvements in clinical assessment and brain imaging, which has enabled clinicians to diagnose AD more reliably and at an earlier stage of illness. Patients classified as having a pre-dementia condition known as Mild Cognitive Impairment (MCI) are at increased risk for progressing to AD or dementia. Thus, American Academy of Neurology Practice Guidelines include recommendations that clinicians identify and monitor MCI using cognitive test batteries. The early diagnosis of dementing illnesses can lead to beneficial pharmacological treatment and non-pharmacological interventions (e.g., caregiver education, legal and financial counseling).

However, several studies have shown that physicians often lack knowledge of the early signs and symptoms of AD resulting in a delay in diagnosis and intervention. Many physicians are also unaware of the advantages and limitations of new assessment tools, or how to interpret their results in clinical practice. Clinicians also need information about the latest AD research to respond to patient questions and to refer to clinical trials.

■ Target Audience

This activity is designed for:

- Neurologists
- Psychiatrists
- Geriatricians & Gerontologists
- Epidemiologists
- Neuropsychologists
- Psychologists
- Neuroscientists

■ Educational Objectives

The purpose of this symposium is to provide a forum for new information and for in-depth discussions about advances in research, related to the clinical diagnosis and progression of Alzheimer's Disease (AD). This symposium will emphasize the early stage of AD and the preclinical deficits that are associated with increased risk for subsequent dementia. We will present results from several longitudinal and cross-sectional studies that have explored clinical, imaging and biomarker features that are related to AD. We will explore how these studies lay the groundwork for making an earlier and more accurate diagnosis of AD.

The symposium will include two keynote addresses and three individually themed symposia, each featuring national experts in the fields of neurology, psychiatry, geriatrics, neuropsychology, radiology, epidemiology and molecular biology. Each mini-symposium will be followed by an extended discussion period, allowing active audience participation to promote a better understanding of the issues.

Upon completion of this symposium, the attendees should be able to:

- Name risk factors for the progression from "normal aging" to MCI and Dementia
- Understand the challenges in interpreting the results of psychometric tests in "normal aging", MCI and early AD
- Describe the course of amyloid load and CSF biomarkers in preclinical AD
- Recognize the changes in early AD on metabolic PET and structural MRI scans
- Describe the rationale for a preclinical and prodromal AD (MCI) diagnosis



■ Distinguished Faculty

Program Director

Ranjan Duara, MD

Medical Director, Wien Center for Alzheimer's Disease and Memory Disorders
Mount Sinai Medical Center, Miami Beach
Departments of Medicine, Neurology and Psychiatry
Miller School of Medicine, University of Miami, Miami, FL
Department of Neurology, University of South Florida College of Medicine, Tampa, FL

Keynote Speakers:

Bruno Dubois, MD

Professor, Fédération de Neurologie
Hôpital de la Salpêtrière
Paris, France

Christopher Rowe, FRACP, MD

Director of Nuclear Medicine and Centre for PET, Austin Hospital
Professorial Fellow at the University of Melbourne
Melbourne, Australia

Distinguished Faculty:

Marilyn Albert, PhD

Director of the Division of Cognitive Neuroscience, Neurology
Director, Alzheimer's Disease Research Center
Johns Hopkins Medical School
Baltimore, Maryland

David Brooks, MD, DSc, FRCP

Hartnett Professor of Neurology
Imperial College
Head, Neurology Group,
Hammersmith Hospital
London, United Kingdom

Anne Fagan, PhD

Research Associate Professor, Neurology
Washington University
St. Louis, Missouri

Howard Feldman, MD, FRCPC

Vice President and Therapeutic Area Head
Global Clinical Research - Neuroscience
Bristol-Myers Squibb
Wallingford, CT, USA

Adam Fleisher, MD

Medical Director, Alzheimer's Disease Cooperative Study Group
Assistant Professor, Neurosciences
University of California
San Diego, California

Mary Ganguli, MD, MPH

Professor of Psychiatry and Epidemiology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Oskar Hansson, MD, PhD

Associate Professor at the Clinical Memory Research Unit
Department of Clinical Sciences
Lund University
Malmö, Sweden

Keith Johnson, MD

Associate Professor of Radiology and Neurology, Harvard University
Associate Radiologist and Director of Molecular Neuroimaging
Massachusetts General Hospital
Boston, Massachusetts

David Loewenstein PhD, ABPP/CN

Professor of Psychiatry and Behavioral Sciences and Neurology
University of Miami Miller School of Medicine
Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai
Miami, Florida

Mark Mintun, MD

Chief Medical Officer
Avid Radiopharmaceuticals
Philadelphia, Pennsylvania

John Morris, MD

Friedman Distinguished Professor of Neurology
Washington University School of Medicine
St. Louis, Missouri

Ronald Petersen, MD, PhD

Professor of Neurology and Alzheimer's Disease Research
Mayo Medical School
Rochester, Minnesota

Rosebud O. Roberts, MB ChB, MS

Associate Professor of Epidemiology, Health Sciences Research
Mayo Clinic
Rochester, Minnesota

Reisa Sperling, MD

Director, Center for Alzheimer Research and Treatment
Brigham and Women's Hospital
Associate Professor of Neurology,
Harvard Medical School
Boston, Massachusetts

Pieter Jelle Visser, MD, PhD

Psychiatry and Neuropsychology,
Maastricht University Medical Centre
Alzheimer's Center, Neurology,
VU University Medical Centre
Amsterdam, The Netherlands

Kathleen A. Welsh-Bohmer, PhD, ABCN

Director, Bryan Alzheimer's Disease Research Center
Duke University
Durham, North Carolina

Robert Wilson, PhD

Professor, Neurological Sciences and Psychology
Rush University Medical Center
Chicago, Illinois

David Wolk, MD

Assistant Professor of Neurology
University of Pennsylvania
Philadelphia, Pennsylvania

Steven Younkin, MD, PhD

Professor of Pharmacology
Mayo Clinic
Jacksonville, Florida



Friday, April 29, 2011

AM

- 7:00 - 8:00 Breakfast Buffet
- 8:00 - 8:15 Welcome and Introduction
Ranjan Duara MD
- 8:15 - 9:00 Keynote Address: Early Diagnosis of AD – Now and the Future
Christopher Rowe, MD
- 9:00-9:15 Break
- 9:15 - 11:30 **Mini-Symposium 1: Risk Factors for Progression from Normal Aging to MCI and Dementia**
Chair: David Loewenstein, PhD
Discussant: Mary Ganguli, MD, MPH
- When is Cognitive Aging Abnormal?
David Loewenstein, PhD
- The Religious Orders Study & the Chicago Health and Aging Project
Robert Wilson, PhD
- The Cache County Study
Kathleen Welsh-Bohmer, PhD
- The Mayo Clinic Study of Aging
Rosebud Roberts, MB, ChB
- The DESCRIPA and Maastricht Studies
Pieter Visser, MD, PhD
- 11:30 - 11:45 Break
- 11:45 - 12:30 Open Discussion
- 12:30 - 1:30 Lunch Break

PM

- 1:30 - 4:15 **Mini-Symposium 2: Studies in Preclinical AD: Diagnosis and Progression**
Chair: Reisa Sperling, MD
Discussant: John Morris, MD
- Proposed Criteria for PreClinical AD
Reisa Sperling, MD
- PiB and Florbetapir PET Imaging in Non-Demented Adults
Mark Mintun, MD
- Genetic Markers Derived from GWAS Studies for Progression to AD
Steven Younkin, MD, PhD
- Longitudinal PiB, MRI and Cognitive Studies and Development of Cognitive Impairment
Christopher Rowe, MD
- CSF Biomarkers of Preclinical AD
Anne Fagan, PhD
- Amyloid Imaging and the Default Network in Normal Aging and MCI
Keith Johnson, MD
- 4:30 - 5:30 Open Discussion
- 5:30 Adjourn

Saturday, April 30, 2011

AM

7:30 - 8:15 Breakfast Buffet

8:15 - 9:00 Keynote Address: Rationale for Prodromal and Preclinical AD Criteria
Bruno Dubois, MD

9:00 - 9:15 Break

9:15 - 11:45 Mini-Symposium 3: Studies in Prodromal AD: Diagnosis and Risk for Progression
Chair: Marilyn Albert, PhD
Discussant: Howard Feldman, MD

Proposed Criteria for MCI due to AD
Marilyn Albert, PhD

Contribution of Cognitive, CSF and MRI Markers to the Progression from MCI to AD: (DESCRIPA Study)
Pieter Visser, MD, PhD

Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers for Predicting Progression to AD (ADNI Study)
Adam Fleisher, MD

Combined rCBF and CSF Biomarkers in Predicting Progression of MCI to AD
Oskar Hansson, MD, PhD

Conversion of PiB Positive and Negative MCI to AD
David Brooks, MD, DSc

Amyloid Imaging in MCI Subtypes and Predictors of Progression to AD
David Wolk, MD

Validation of New Criteria: What Will it Take?
Ronald Petersen, MD, PhD

11:45 - 12:00 Break

12:00 - 12:45 Open Discussion

12:45 Adjourn



Registration Information

■ Method of Registration

To register by mail or fax:

Please complete the registration form and send it with the payment to the above mailing address or fax number.

To register by email: provide the information requested on the registration form in an e-mail message and send to:
mcisymposium@msmc.com

To register by internet:

www.mcisymposium.org

Registration confirmations will be issued.

Payment:

Registration fees can be paid by credit card or check, no cash is accepted.

Please make all checks payable to:

MOUNT SINAI MEDICAL CENTER

Registration Fee Inclusions:

Registration fees include admittance to all the scientific conferences, conference materials, breakfast, lunch on the first day, refreshment breaks.

Registration Hours:

The conference registration desk will be staffed:

Thursday, April 28	4:00 pm – 7:00pm
Friday, April 29	7:00 am - 5:00 pm
Saturday, April 30	7:30 am - 12:30 pm

■ Symposium Location

Eden Roc Hotel:

4525 Collins Avenue, Miami Beach, Florida 33140

Phone: (800) 468-3571 or (305) 531-0000

Web-Site: www.marriott.com/miasr



The place to experience Miami Beach... On magnificently landscaped oceanfront grounds, the new Eden Roc brings dynamic design, unsurpassed luxury and cutting-edge technology together in one place – the place to be on Miami Beach. Following a \$200 million dollar renovation and expansion, the bold new Eden Roc, A Renaissance Beach



Resort and Spa, embraces its role as a timeless treasure, yet welcomes guests with a contemporary spirit. In this stunning locale, a pulsing nightlife, brilliant white-sand beaches, and sizzling culture combine for the perfect getaway. At the Eden Roc Hotel you will savor the best of this colorful city.

■ DRESS

Business casual attire is appropriate for all events. A light sweater or jacket is recommended in the meeting rooms.

■ Hotel Reservations

For the convenience of the 9th Annual Mild Cognitive Impairment Symposium, a limited number of rooms have been reserved at the special daily rate of \$189 (single or double occupancy, plus resort fees, state and local taxes). To receive this conference rate, reservations must be made directly with the Eden Roc Hotel and you must mention that you are a registrant of the 9th Annual Mild Cognitive Impairment Symposium. Rooms will be held at the special rate until April 14, 2011. Rooms at the discounted rate will be allocated on a first-come, first-served basis. Reservations received after the cut-off date are subject to availability and prevailing rates.

Mount Sinai Medical Center is committed to making its CME activities accessible to all individuals. If you are in need of an accommodation, please do not hesitate to call and/or submit a description of your needs in writing within 5 weeks of the activity in order to receive service.

FOR ROOM RESERVATIONS CALL: (800) 468-3571 or (305) 531-0000
OR ACCESS THE HOTEL WEB SITE VIA www.marriott.com/miasr

SYMPOSIUM ON MILD COGNITIVE IMPAIRMENT

■ THREE EASY WAYS TO REGISTER FOR THE MILD COGNITIVE IMPAIRMENT SYMPOSIUM 2011:

ONLINE:

www.mcisymposium.org

FAX:Attn: Warren Barker
(305) 674-2259**MAIL:**Warren Barker
Wien Center
4300 Alton Road
Miami Beach, FL 33140

■ REGISTRANT INFORMATION Please print:

LAST NAME FIRST NAME MIDDLE NAME

DEGREE: ☐ MD ☐ DO ☐ PhD ☐ OTHER _____

INSTITUTION / ORGANIZATION _____

STREET ADDRESS _____

CITY STATE ZIP CODE COUNTRY

E-MAIL TELEPHONE

■ REGISTRATION FEES:

Physicians:

- ☐ \$340.00 (if dated/postmarked by March 31)
☐ \$390.00 (if dated/postmarked after March 31)
☐ \$440.00 (on site registration)

Non-Physicians:

- ☐ \$225.00 (if dated/postmarked by March 31)
☐ \$275.00 (if dated/postmarked after March 31)
☐ \$325.00 (on site registration)

Students:

- ☐ \$100.00

■ PAYMENT METHOD:

☐ American Express ☐ Master Card ☐ Visa ☐ Check in the amount of _____

Card No. _____ Expiration Date ____/____

Cardholder's Name _____

Signature _____

NAME & ADDRESS ON CARD IF DIFFERENT THAN ABOVE _____

Payment must accompany registration form. Refund Policy: Full refund will be given if written notice is received not later than April 15, 2011. All refunds will be processed after the meeting. No refunds will be made on cancellations received after that date.

How did you find out about this meeting? _____